| 1101 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
41 |
| 1102 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
France |
48 |
| 1103 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Sweden |
64 |
| 1104 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
63 |
| 1105 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
64 |
| 1106 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
58 |
| 1107 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome, Myeloproliferative Neoplasms |
Hematology |
2025 |
Standard Therapy |
Poland |
68 |
| 1108 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome, Myeloproliferative Neoplasms |
Hematology |
2025 |
Standard Therapy |
Germany |
59 |
| 1109 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
56 |
| 1110 |
Apheresis |
Allogeneic |
Diffuse Large B-cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
Belarus |
53 |
| 1111 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
60 |
| 1112 |
Apheresis |
Allogeneic |
Immunodeficiency – LRBA |
Hematology |
2025 |
Standard Therapy |
Turkey |
14 |
| 1113 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
Poland |
20 |
| 1114 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
65 |
| 1115 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Ukraine |
54 |
| 1116 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
75 |
| 1117 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
58 |
| 1118 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
Poland |
48 |
| 1119 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
37 |
| 1120 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Chile |
40 |
| 1121 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
72 |
| 1122 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Switzerland |
65 |
| 1123 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2025 |
Standard Therapy |
Portugal |
68 |
| 1124 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Estonia |
9 |
| 1125 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2025 |
Standard Therapy |
USA |
63 |
| 1126 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Sweden |
67 |
| 1127 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Lithuania |
45 |
| 1128 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
59 |
| 1129 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Poland |
69 |
| 1130 |
Apheresis |
Autologous |
T-cell lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
64 |
| 1131 |
Apheresis |
Allogeneic |
Acute lymphoblastic leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
42 |
| 1132 |
Apheresis |
Autologous |
Primary central nervous system lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
64 |
| 1133 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome/ Acute Myeloid Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
62 |
| 1134 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
42 |
| 1135 |
Apheresis |
Autologous |
T-cell lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
55 |
| 1136 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
72 |
| 1137 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
58 |
| 1138 |
Apheresis |
Autologous |
Central nervous system lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
65 |
| 1139 |
Apheresis |
Autologous |
Follicular lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
67 |
| 1140 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
70 |
| 1141 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
60 |
| 1142 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Portugal |
64 |
| 1143 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Portugal |
63 |
| 1144 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
67 |
| 1145 |
Apheresis |
Autologous |
Acute myeloid leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
60 |
| 1146 |
Apheresis |
Autologous |
Hodgkin lymphoma rezidiv |
Hematology |
2025 |
Standard Therapy |
Germany |
65 |
| 1147 |
Apheresis |
Autologous |
Non-Hodgkin lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
64 |
| 1148 |
Apheresis |
Autologous |
T-cell lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
67 |
| 1149 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
70 |
| 1150 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
62 |
| 1151 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
62 |
| 1152 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
66 |
| 1153 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
55 |
| 1154 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Poland |
60 |
| 1155 |
Apheresis |
Allogeneic |
Fanconi's Anemia |
Hematology |
2025 |
Standard Therapy |
Ukraine |
6 |
| 1156 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
69 |
| 1157 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Lithuania |
54 |
| 1158 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Macedonia |
56 |
| 1159 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
CROATIA |
64 |
| 1160 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
75 |
| 1161 |
Apheresis |
Allogeneic |
T-cell Lymphoma |
Hematology |
2025 |
Standard Therapy |
NETHERLANDS |
65 |
| 1162 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
65 |
| 1163 |
Apheresis |
Allogeneic |
Myeloid Sarcoma |
Hematology |
2025 |
Standard Therapy |
Brazil |
48 |
| 1164 |
Apheresis |
Allogeneic |
T-cell Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
17 |
| 1165 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
13 |
| 1166 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2025 |
Standard Therapy |
USA |
69 |
| 1167 |
Apheresis |
Allogeneic |
T-cell Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
13 |
| 1168 |
Apheresis |
Allogeneic |
B-cell Precursor Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Slovakia |
67 |
| 1169 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
72 |
| 1170 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Italy |
52 |
| 1171 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Belgium |
64 |
| 1172 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2025 |
Standard Therapy |
Italy |
68 |
| 1173 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Canada |
56 |
| 1174 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
64 |
| 1175 |
Apheresis |
Allogeneic |
Other Myelofibrosis/Myelosclerosis |
Hematology |
2025 |
Standard Therapy |
USA |
55 |
| 1176 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
64 |
| 1177 |
Apheresis |
Allogeneic |
Myelodysplastic disorder |
Hematology |
2025 |
Standard Therapy |
France |
63 |
| 1178 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
63 |
| 1179 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
20 |
| 1180 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
France |
23 |
| 1181 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
USA |
73 |
| 1182 |
Apheresis |
Allogeneic |
Inherited Immune System Disorder |
Hematology |
2025 |
Standard Therapy |
France |
9 |
| 1183 |
Apheresis |
Allogeneic |
Lymphoma – DLBCL |
Hematology |
2025 |
Standard Therapy |
United Kingdom |
55 |
| 1184 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
61 |
| 1185 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2025 |
Standard Therapy |
Lithuania |
58 |
| 1186 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2025 |
Standard Therapy |
Germany |
73 |
| 1187 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
35 |
| 1188 |
Apheresis |
Allogeneic |
Chronic myelomonocytic leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
65 |
| 1189 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2025 |
Standard Therapy |
Germany |
70 |
| 1190 |
Apheresis |
Allogeneic |
Acute myeloid leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
66 |
| 1191 |
Apheresis |
Autologous |
Diffuse large B-cell lymphoma |
Hematology |
2025 |
Standard Therapy |
Germany |
42 |
| 1192 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Netherlands |
65 |
| 1193 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
60 |
| 1194 |
Apheresis |
Allogeneic |
Post Mielofibrosis |
Hematology |
2025 |
Standard Therapy |
Poland |
66 |
| 1195 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
74 |
| 1196 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Poland |
17 |
| 1197 |
Apheresis |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2025 |
Standard Therapy |
USA |
72 |
| 1198 |
Apheresis |
Allogeneic |
T-cell prolymphocytic leukemia |
Hematology |
2025 |
Standard Therapy |
New Zealand |
64 |
| 1199 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2025 |
Standard Therapy |
Germany |
62 |
| 1200 |
Apheresis |
Allogeneic |
Mielofibrosis |
Hematology |
2025 |
Standard Therapy |
Finland |
68 |